tiprankstipranks
Genscript Biotech (HK:1548)
HKEX:1548

Genscript Biotech (1548) Stock Price & Analysis

4 Followers

1548 Stock Chart & Stats

Day’s RangeHK$0 - HK$0
52-Week RangeHK$7.43 - HK$24.95
Previous CloseHK$13.08
Volume28.36M
Average Volume (3M)17.56M
Market Cap
HK$27.68B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)
Beta1.10
Aug 28, 2024
-HK$0.08
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding2,124,027,670
10 Day Avg. Volume5,514,000
30 Day Avg. Volume17,563,148
Standard Deviation0.24
R-Squared0.11
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
Price Target Upside49.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2

Options Prices

Currently, No data available
---

Ownership Overview

0.00%1.77%4.37%93.85%
0.00%
Insiders
4.37% Other Institutional Investors
93.85% Public Companies and
Individual Investors

1548 FAQ

What was Genscript Biotech’s price range in the past 12 months?
Genscript Biotech lowest stock price was HK$7.43 and its highest was HK$24.95 in the past 12 months.
    What is Genscript Biotech’s market cap?
    Currently, no data Available
    When is Genscript Biotech’s upcoming earnings report date?
    Genscript Biotech’s upcoming earnings report date is Aug 28, 2024 which is in 37 days.
      How were Genscript Biotech’s earnings last quarter?
      Genscript Biotech released its earnings results on Mar 10, 2024. The company reported -HK$0.492 earnings per share for the quarter, missing the consensus estimate of -HK$0.391 by -HK$0.102.
        Is Genscript Biotech overvalued?
        According to Wall Street analysts Genscript Biotech’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Genscript Biotech pay dividends?
          Genscript Biotech pays a Notavailable dividend of HK$0.09 which represents an annual dividend yield of N/A. See more information on Genscript Biotech dividends here
            What is Genscript Biotech’s EPS estimate?
            Genscript Biotech’s EPS estimate is -HK$0.08.
              How many shares outstanding does Genscript Biotech have?
              Genscript Biotech has 2,127,686,500 shares outstanding.
                What happened to Genscript Biotech’s price movement after its last earnings report?
                Genscript Biotech reported an EPS of -HK$0.492 in its last earnings report, missing expectations of -HK$0.391. Following the earnings report the stock price went down -6.563%.
                  Which hedge fund is a major shareholder of Genscript Biotech?
                  Currently, no hedge funds are holding shares in HK:1548
                  ---

                  Genscript Biotech Stock Smart Score

                  Company Description

                  Genscript Biotech

                  Genscript Biotech Corp an investment holding company. It is involved in fundamental life sciences research, translational biomedical research, and early-stage pharmaceutical development businesses. The company segments include bio-science services and products, biologics development services, industrial synthetic biology products, and cell therapy. It generates maximum revenue from the bio-science services and products. Geographically, it derives majority revenue from North America and also has a presence in Europe, China, Asia Pacific, Japan, and Other Countries.
                  ---

                  1548 Stock 12 Month Forecast

                  Average Price Target

                  HK$19.52
                  ▲(49.27% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"HK$8","23":"HK$23","11.75":"HK$11.75","15.5":"HK$15.5","19.25":"HK$19.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22.9999995810665,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">HK$23.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.524625,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">HK$19.52</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.999999708568,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">HK$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,11.75,15.5,19.25,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2023","6":"Jan<br/>2024","9":"Apr<br/>2024","12":"Jul<br/>2024","25":"Jul<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.19,10.252307660082039,11.314615320164076,12.376922980246114,13.439230640328153,14.501538300410193,15.56384596049223,16.626153620574268,17.688461280656306,18.750768940738347,19.813076600820384,20.875384260902422,21.937691920984463,{"y":22.9999995810665,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.19,9.984971153846153,10.779942307692307,11.574913461538461,12.369884615384615,13.164855769230769,13.959826923076923,14.754798076923077,15.54976923076923,16.344740384615385,17.13971153846154,17.934682692307693,18.729653846153845,{"y":19.524625,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.19,9.713846131428307,10.237692262856616,10.761538394284923,11.28538452571323,11.809230657141537,12.333076788569846,12.856922919998153,13.380769051426462,13.90461518285477,14.428461314283076,14.952307445711384,15.476153577139693,{"y":15.999999708568,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.3,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":18.38,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.65,"date":1695945600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.3,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.45,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.5,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.66,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.84,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.2,"date":1710460800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.54,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.4,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.19,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Gilead Sciences
                  Becton Dickinson
                  Qiagen
                  Vertex Pharmaceuticals
                  Genscript Biotech

                  Best Analysts Covering 1548

                  1 Year
                  Ziyi ChenGoldman Sachs
                  1 Year Success Rate
                  0/2 ratings generated profit
                  0%
                  1 Year Average Return
                  -30.00%
                  reiterated a buy rating 4 months ago
                  Copying Ziyi Chen's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -30.00% per trade.
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis